阿巴卡韦,临床注释-2,变异和临床注释数据

阿巴卡韦

临床注释ID

981419257

药物名称(英)

abacavir

变异单倍型

HLA-B*57:01:01

基因

HLA-B

证据级别

1A

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Toxicity

表现型类别

毒性

分数

325.75

PMID计数

11

计数的证据

14

表现型

药物过敏；HIV感染

表现型(英)

Drug Hypersensitivity;HIV Infections

最新日期

2021/3/24 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/981419257

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
955	*57:01:01	Patients with one or two copies of the HLA-B57:01:01 allele have an increased risk of hypersensitivity to abacavir as compared to patients with no HLA-B57:01:01 alleles or negative for the HLA-B*57:01:01 test. Other genetic and clinical factors may also influence the risk of abacavir-induced adverse reactions.

临床证据

id	证据的ID	总结
1744	1448260768	HLA-B *57:01:01 is associated with risk of Drug Hypersensitivity when treated with abacavir in people with HIV.
1743	1448255629	HLA-B *57:01:01 is associated with Drug Hypersensitivity when treated with abacavir in people with HIV.
1742	1444877145	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.
1741	1444877117	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.
1740	1444876870	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.
1739	1444707690	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.
1738	1444705964	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.
1737	981476261	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.
1736	981475111	HLA-B *57:01:01 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV.
1735	981349377	HLA-B *57:01:01 is associated with increased likelihood of Drug Hypersensitivity when treated with abacavir in people with HIV.
1734	981349371	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.
1733	PA166104833	Annotation of FDA Label for abacavir and HLA-B
1732	PA166104991	Annotation of DPWG Guideline for abacavir and HLA-B
1731	PA166104997	Annotation of CPIC Guideline for abacavir and HLA-B

临床病史

id	类型	评论
681	Update	CA score added as part of scoring system release. LOE assigned following curator review.
680	Update	Removed VA where no individuals had the HLA-B*5701 allele
679	Update	Removed override
678	Update	Attached CPIC, Dutch guidelines and FDA label
677	Update	Added reason for override. Guidelines and FDA label
676	Update

最新招商产品更多>>